Pharmacokinetics (PK) and tolerability of single and multiple doses of bosentan, an oral dual endothlein receptor antagonist, in children with pulmonary arterial hypertension

被引：0
|
作者：
Barst, RJ
Ivy, D
Widlitz, AC
Moore, K
Doran, A
van Giersbergen, P
Nguyen, N
Gaitonde, MD
机构：
[1] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA
[2] Univ Colorado, Childrens Hosp, Denver, CO 80202 USA
[3] Actelion Pharmaceut Ltd, Allschwil, Switzerland
来源：
CIRCULATION | 2002年 / 106卷 / 19期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2239
引用
收藏
页码：450 / 450
页数：1
相关论文
共 50 条
  • [21] Safety, Tolerability and Pharmacokinetics of Single Ascending and Multiple Oral Doses of Tegoprazan in Healthy Chinese Subjects
    Jinjie He
    Guoying Cao
    Jicheng Yu
    Jingjing Wang
    Nengneng Cheng
    Jufang Wu
    Jing Zhang
    Xiaojie Wu
    Basheng Zhang
    Jiayan Lu
    Shangzhi Chen
    Clinical Drug Investigation, 2021, 41 : 89 - 97
  • [22] Safety, tolerability and pharmacokinetics of single and multiple doses of a novel sigma-1 receptor antagonist in three randomized phase I studies
    Abadias, Montserrat
    Escriche, Marisol
    Vaque, Anna
    Sust, Mariano
    Encina, Gregorio
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (01) : 103 - 117
  • [23] BOSENTAN AN ORAL NONSELECTIVE ENDOTHELIN (ET) RECEPTOR ANTAGONIST, BLUNTS MONOCROTALINE-INDUCED PULMONARY-HYPERTENSION
    HILL, NS
    WARBURTON, RR
    PIETRAS, LA
    KLINGER, JR
    FASEB JOURNAL, 1995, 9 (03): : A600 - A600
  • [24] Long-term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics
    White, R. James
    Parikh, Keyur
    Allen, Roblee
    Feldman, Jeremy
    Jerjez-Sanchez, Carlos
    Pan, Lei
    Keogh, Anne
    Vizza, C. Dario
    Shapiro, Shelley
    Gordon, Kathryn
    Broderick, Meredith
    Bartolome, Sonja
    PULMONARY CIRCULATION, 2020, 10 (04)
  • [25] The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension
    Steriade, Alexandru
    Seferian, Andrei
    Jais, Xavier
    Savale, Laurent
    Jutant, Etienne-Marie
    Parent, Florence
    Sitbon, Olivier
    Humbert, Marc
    Simonneau, Gerald
    Montani, David
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2014, 8 (03) : 84 - 92
  • [26] Treatment of pulmonary arterial hypertension (PAH) with oral endothelin-receptor antagonist bosentan in systemic sclerosis: BREATHE-1 trial and clinical experience
    Ahmadi-Simab, K
    Lamprecht, P
    Hellmisch, B
    Gross, WL
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2004, 63 (06): : 495 - 497
  • [27] SYSTEMATIC EVALUATION OF GENETIC DETERMINANTS OF HEPATOTOXICITY FROM THE ENDOTHELIN RECEPTOR ANTAGONIST BOSENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH)
    Seyfarth, Hans-Juergen
    Favreau, Nadine
    Tennert, Carsten
    Rosendahl, Jonas
    Ruffert, Claudia
    Halank, Michael
    Wirtz, Hubert
    Moessner, Joachim
    Kovacs, Peter
    Wittenburg, Henning
    HEPATOLOGY, 2011, 54 : 530A - 531A
  • [28] Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension
    Hatano, Masaru
    Yamada, Hidehiro
    Fukuda, Keiichi
    Yoshioka, Koichiro
    Funauchi, Masanori
    Kuwana, Masataka
    Sata, Masataka
    Taniguchi, Mitsugu
    Nakanishi, Norifumi
    Saito, Takefumi
    Saji, Tsutomu
    Sasayama, Shigetake
    HEART AND VESSELS, 2015, 30 (06) : 798 - 804
  • [29] Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension
    Masaru Hatano
    Hidehiro Yamada
    Keiichi Fukuda
    Koichiro Yoshioka
    Masanori Funauchi
    Masataka Kuwana
    Masataka Sata
    Mitsugu Taniguchi
    Norifumi Nakanishi
    Takefumi Saito
    Tsutomu Saji
    Shigetake Sasayama
    Heart and Vessels, 2015, 30 : 798 - 804
  • [30] Exploring the pharmacokinetics and tolerability of cyclooxygenase inhibitor ampiroxicam: a phase I study on single and multiple oral doses
    Zhao, Pengfei
    Qi, Ying
    FRONTIERS IN PHARMACOLOGY, 2024, 15
12345